Skip to main content Back to Top
Advertisement

2/25/2020

Levetiracetam Extended-Release Tablets

Products Affected - Description

    • Levetiracetam oral extended release tablet, Lupin, 500 mg, bottle, 60 count, NDC 68180-0117-07
    • Levetiracetam oral extended release tablet, Lupin, 750 mg, bottle, 60 count, NDC 68180-0118-07
    • Levetiracetam oral extended release tablet, Sun Pharma, 500 mg, bottle, 60 count, NDC 47335-0573-86
    • Levetiracetam oral extended release tablet, Sun Pharma, 750 mg, bottle, 60 count, NDC 47335-0576-86

Reason for the Shortage

    • Lupin did not provide a reason for the shortage.
    • OWP is discontinuing their Roweepra XR formulations.
    • Sun Pharma did not provide a reason for the shortage.
    • Torrent is not selling their levetiracetam extended-release tablets within the US.

Available Products

    • Keppra XR oral extended release tablet, UCB, 500 mg, bottle, 60 count, NDC 50474-0598-66
    • Keppra XR oral extended release tablet, UCB, 750 mg, bottle, 60 count, NDC 50474-0599-66
    • Levetiracetam oral extended release tablet, Apotex, 500 mg, bottle, 60 count, NDC 60505-3280-06
    • Levetiracetam oral extended release tablet, Apotex, 750 mg, bottle, 60 count, NDC 60505-3517-06

Estimated Resupply Dates

    • Lupin has levetiracetam 500 mg and 750 mg extended-release tablets on intermittent back order and the company is releasing product as it becomes available.
    • Sun Pharma has levetiracetam 500 mg and 750 mg extended-release tablets on back order and the company cannot estimate a release date.

Updated

Updated February 25, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created August 6, 2019 by Anthony Trovato, PharmD, BCPS. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins